Modeling of antibody-drug conjugate pharmacokinetics

Obtenir text complet
Series

The pharmacokinetics of therapeutic proteins

Obtenir text complet

AI and big data in drug discovery

Obtenir text complet
Series

Patient heterogeneity in dose-finding trials part 1, methods for 2 groups/

Obtenir text complet
Series

Patient heterogeneity in dose-finding trials part 2, more than 2 groups /

Obtenir text complet
Series

Implementation of adaptive methods in early phase clinical trials

Obtenir text complet
Series

Emerging big data in medicinal chemistry promiscuity analysis as an example /

Obtenir text complet
Series

Adaptive clinical trials conclusion and future directions /

Obtenir text complet
Series

Adaptive clinical trials overview, part 2 of 2 /

Obtenir text complet
Series

Ligand-based drug design

Obtenir text complet

Structure-based drug design

Obtenir text complet

Arylamine N-acetyltransferases part 2 of 3 /

Obtenir text complet
Series

Arylamine N-acetyltransferases part 3 of 3 /

Obtenir text complet
Series

Arylamine N-acetyltransferases part 1 of 3 /

Obtenir text complet
Series

Antisense oligonucleotides the promise and the problems /

Obtenir text complet
Series

Bacterial vaccines in development part 1 of 2 /

Obtenir text complet
Series

Bacterial vaccines in development part 2 of 2 /

Obtenir text complet
Series

A systems biology approach to drug development clinical testing of biomarkers for the anti-ErbB3 antibody MM-121 /

Obtenir text complet
Series

Teixobactin kills pathogens without detectable resistance

Obtenir text complet
Series (Antibiotic resistance)
Series (Small molecule drug discovery)

Pharmacometrics in psychiatry

Obtenir text complet